Sponsored

Significant risk remains for companies that cannot move quickly enough to positively impact R&D productivity and for those that encounter challenges in accessing technology and expertise that likely lie outside their organization.

For multiple perspectives on addressing this challenge, three respected individuals involved with the effort to bridge clinical research and clinical health care share their views.

For most biopharma sponsors, the crux of their challenge is how to identify an adequate number of evaluable patients to sufficiently power their late phase clinical research.